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Abstract
Background: Src homology 2 (SH2) domain is a conserved module involved in various biological processes. Tensin family
member was reported to be involved in tumor suppression by interacting with DLC-1 (deleted-in-liver-cancer-1) via its SH2
domain. We explore here the important questions that what the structure of tensin2 SH2 domain is, and how it binds to
DLC-1, which might reveal a novel binding mode.
Principal Findings: Tensin2 SH2 domain adopts a conserved SH2 fold that mainly consists of five b-strands flanked by two
a-helices. Most SH2 domains recognize phosphorylated ligands specifically. However, tensin2 SH2 domain was identified to
interact with nonphosphorylated ligand (DLC-1) as well as phosphorylated ligand.
Conclusions: We determined the solution structure of tensin2 SH2 domain using NMR spectroscopy, and revealed the
interactions between tensin2 SH2 domain and its ligands in a phosphotyrosine-independent manner.
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Introduction
Src homology 2 (SH2) domain was firstly identified from N-
terminal noncatalytic region of fujinami sarcoma virus P130
gag-fps.I t
is a conserved domain of approximately 100 residues and shared by
a number of cytoplasmic tyrosine kinase [1]. Few years after its
identification, the SH2 domain was found in various proteins other
than tyrosine kinases, such as PLCc1, RasGAP, Grb2, suggesting its
role as an interaction module [2]. Meanwhile, the works on GAP
and EGF receptorverified the interactions between the SH2 domain
and phosphorylated tyrosine (pTyr) containing protein [3–5].
Post-translational modification by phosphate group is a highly
dynamic process, which is critical for regulation of various cellular
events. Especially, phosphorylation/dephosphorylation of tyrosine
residues of intracellular proteins is a critical signal for multiple
biological events, e.g. DNA replication and repair, chromosome
recombination and segregation, motility, metabolism, and gene
transcription [6]. The diverse functions of SH2 domain containing
proteins require broad but specific recognition of pTyr-ligands.
Structural analyses of different SH2 domains revealed some
common features of their structures and the binding between the
SH2 domains and their ligands: (1) The SH2 domain mainly
contains five anti-parallel b-strands flanked by two a-helices [7].
(2) The SH2 domain has two binding regions: one is the pTyr
binding site, a deep positive-charged pocket [8], the other is the so-
called ‘‘specificity determine region’’, which includes residues close
to the pTyr binding site [7–10]. It is revealed that the C-terminal
three residues adjacent to pTyr are critical for the affinity and
specificity of SH2 domain-ligand interaction [9,10]. These provide
SH2 domain containing proteins with properties of precise
recognition of ligands and efficient regulation of signaling
pathway. On the other hand, the SH2 domains binding pTyr
through variable C-termini may facilitate SH2 containing proteins
interacting with various ligands [7]. In most cases, SH2 domain-
ligand binding is dependent on phosphorylated tyrosine.
Tensin is a family of proteins localized to focal adhesions of cells
[11]. Tensin family has four members: tensin1, tensin2, tensin3
and cten. All these four tensins are proteins with multidomain,
which allow tensins to interact with several ligands simultaneously.
This property of tensin family reflects its essential role in signal
transduction pathway. Although the sequence similarity between
tensin members is low, they share some common features at N-
terminus and C-terminus. For instance, all tensins have a SH2
domain and a phosphotyrosine binding domain (PTB domain) at
C-terminus. In addition, tensin1, tensin2, tensin3 all possess actin
binding domain (ABD) and focal adhesion binding site (FAB) at N-
terminus [11]. Previous studies suggested that tensin2 interacts
with DLC1 through PTB domain as well as SH2 domain [12].
Although PTB domain of tensin2 has been reported to play a more
dominant role than tensin2 SH2 domain in recognizing DLC1
[12], SH2 domain in other tensin members seems to be
preferential in DLC-1 recognition [13].
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and tumorigenesis by showing a role of tensin3 in maintaining the
transformed properties of cell lines from advanced cancers [14].
More recently, cten was considered to be a potential tumor
suppressor by interacting with DLC-1 (deleted-in-liver-cancer-1), a
member of RhoGTPase activating protein (GAP) family known to
have suppressive activities in tumorigenicity and cancer metastasis
[12,13,15–18]. This interaction was mediated by the SH2 domain
of cten and the fragment ‘‘CSRLSIY
442DNVPG’’ of DLC-1 [13].
Further experiments revealed that the interactions between cten
SH2 domain and DLC-1 are phosphortyrosine independent [13].
This phosphorylation independent manner has also been observed
for the SH2 domain-ligand binding of SAP, Grb7, and Vav1
[7,13,18–20], which might indicate a new binding mode of the
SH2 domain.
In this study, we identified the interactions between the SH2
domain of tensin2, one member of tensin family, and the fragment
‘‘CSRLSIY
442DNVPG’’ of DLC-1. Similar to cten, the interac-
tions between the SH2 domain of tensin2 and DLC-1 were
phosphortyrosine independent. The solution structure of tensin2
SH2 domain was determined by Nuclear Magnetic Resonance
(NMR) spectroscopy. Tensin2 SH2 domain adopted a typical SH2
fold. Furthermore, chemical shift perturbation indicated a similar
manner of tensin2 SH2 domain in binding to nonphosphorylated
and phosphorylated ligands.
Materials and Methods
Sequence analysis
Sequence alignments were performed using ClustalW2 [21].
Further processing of the alignment files was carried out using
ESPript 2.2 [22]. The existence of the SH2 domain in tensin2 was
determined using SMART (http://smart.embl-heidelberg.de/).
Accession number of the proteins used for alignments are listed as
follows: Swiss-Prot, O60880, Homo sapiens SH2_SAP; Swiss-Port,
P16277, Mus musculus SH2_BIK; Swiss-Port, Q56XZ1, Arabidopsis
thaliana SH2_SHB; Swiss-Prot, P23615.1, Saccharomyces cerevisiae
SH2_SPT6; Swiss-Prot, Q63HR2.2, Homo sapiens SH2_tensin2;
Swiss-Prot, Q9HBL0, Homo sapiens SH2_tensin1; Swisst-Prot,
Q68CZ2, Homo sapiens SH2_tensin3; and Swiss-Prot, Q8IZW8,
Homo sapiens SH2_cten.
Protein expression and purification
Sequence encoding the SH2 domain of human tensin2 was
amplified and cloned into pET-22b (Novagen). Following primers
were used for polymerase chain reaction (PCR): forward primer 59-
CCGCATATGGATACATCCAAGTTCTGGTAC-39and reverse
primer 59-TTCTCGAGTTTGCTGGGAATGCGCAGGCAGC-
AfoG-39(restrictionendonucleasesitesunderlined).Therecombinant
tensin2 SH2 domain contained a C-terminal tag of six histidine
residues. The recombinant protein was expressed in Escherichia coli
strainBL21Gold(DE3)andpurifiedaccordingtopreviousprocedure
[23].
15N-labeled and
13C,
15N-labeled tensin2 SH2 domain were
prepared in the same way, except that super broth was replaced by
M9 medium containing 0.5 g/L
15N-labeled ammonium chloride
and 2.5 g/L
13C-labeled glucose as the sole nitrogen source and
carbon source, respectively. The purified protein was dialyzed with
buffer containing 20 mM NaH2PO4, 150 mM NaCl, 50 mM
arginine, 50 mM glutamine and 2 mM EDTA, pH 6.8, and
concentrated to 0.6 mM for further NMR experiments.
Site-directed mutagenesis
The site-directed mutagenesis (Y41S) was performed by PCR
with the previousely constructed plasmid containing gene of
Tensin2 SH2. The following primer sets were used: forward
primer, 59- CATTCATTCCAAGGAGCTTCTGGGCTGGCC-
CTCAAG -39, reverse primer, 59- GCCACCTTGAGGGCCAG-
CCCAGAAGCTCCTTGGAATG -39. The PCR products were
digested with DpnI (TaKaRa) for 10 hours, and then transformed
into E. coli BL21. The plasmids containing mutated gene were
sequenced to confirm the Y41S mutagenesis. The tensin2 SH2
(Y41S) were prepared as described above for further study.
Peptide synthesis
Peptides ‘‘CSRLSIY
442DNVPG’’ and ‘‘CSRLSI pY
442DNVPG’’
(residues 436–447 of DLC-1 with Y
442 nonphosphorylated/phos-
phorylated) were synthesized by GL Biochem (shanghai). The
peptides were purified by HPLC (purity of peptides .95%), and
molecular weight of peptides were confirmed by MS analysis.
Surface plasmon resonance (SPR)
Real-time interactions between tyrosine-phosphorylated or
nonphosphorylated peptide and tensin2 SH2 domain or mutated
tensin2 SH2 domain (Y41S) were measured by surface plasmon
resonance (SPR) on a Biacore 3000 (Biacore Inc.). SPR
experiments were performed on sensor chips CM5 (carboxy-
methylated dextran, BiacoreAB). Chip was treated as described
previously [23]. Purified tensin2 SH2 domain and mutated tensin2
SH2 domain were diluted with running buffer (20 mM NaH2PO4,
150 mM NaCl, 50 mM arginine, 50 mM glutamine and 2 mM
EDTA, pH 6.8). The kinetic analysis of the interactions between
phosphorylated peptide and tensin2 SH2 domain was performed
at 6-step concentration of tensin2 SH2 domain (0.18 mM,
0.38 mM, 0.75 mM, 1.50 mM, 3.00 mM, and 6.00 mM) at a flow
rate of 30 mL/min for 2 min, whereas the kinetic analysis of the
interactions between nonphosphorylated peptide and tensin2 SH2
domain was performed at 6-step concentration of tensin2 SH2
domain (0.41 mM, 0.81 mM, 1.63 mM, 3.25 mM, 6.50 mM, and
13.00 mM). The kinetic analysis of the interactions between
phosphorylated peptide and mutated tensin2 SH2 (Y41S) domain
was performed at 6-step concentration of mutated tensin2 SH2
(Y41S) domain (0.50 mM, 1.00 mM, 2.00 mM, 4.00 mM, 8.00 mM,
and 16.00 mM) at a flow rate of 30 mL/min for 2 min, whereas the
kinetic analysis of the interactions between nonphosphorylated
peptide and mutated tensin2 SH2 domain (Y41S) was performed
at 6-step concentration of mutated tensin2 SH2 domain (Y41S)
(3.13 mM, 6.25 mM, 12.50 mM, 25.00 mM, 50.00 mM, and
100.00 mM). All analyses were performed three times. To
overcome refractive index changes, data of control surface were
subtracted from that of peptide-immobilized surface. Interactions
between peptide and Albumin Bovine V (BSA, Sigma, 8 mg/mL)
were measured as a negative control. Kinetic analyses of SPR data
were performed using BIAevaluation 4.1 (Biacore Inc.). Curves
were fitted with 1:1 (langmuir) binding model. The equilibrium
dissociation constant (KD) was derived from kinetic analysis.
Circular dichroism (CD) spectroscopy
CD experiments were performed on a Jasco-810 spectropho-
tometer (JASCO, Japan) over the wavelength range from 200 to
260 nm at 20uC. Tensin2 SH2 domain was dissolved in buffer
(20 mM NaH2PO4, 150 mM NaCl, 50 mM arginine, 50 mM
glutamine and 2 mM EDTA, pH 6.8) to a concentration of
,0.6 mg/mL. Different molar ratios of SH2/peptide (1:1, 1:2 and
1:3) were prepared in the same buffer. Measurements were taken
in a 1 mm path-length quartz cuvette at a rate of 50 nm/min and
data pitch of 1 nm. CD spectra of the peptides at corresponding
concentrations were measured as control and subtracted. Three
Tensin2 SH2 Domain Binds Nonphosphorated DLC-1
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spectra were performed using Jascow32 software (JASCO, Japan).
NMR spectroscopy, data processing and structure
calculation
NMR samples were dissolved in buffer containing 20 mM
NaH2PO4, 150 mM NaCl, 50 mM arginine, 50 mM glutamine,
2 mM EDTA, 90% H2O/10% D2O and pH 6.8. All NMR
measurements were performed at 293 K on a Bruker DMX500
spectrometer. The following spectra were recorded to obtain
backbone and side chain resonance assignments:
1H-
15N HSQC,
HNCO, HN(CA)CO, CBCA(CO)NH, CBCANH, H(CC)ONH,
HBHA(CO)NH, HC(CO)NH. 3D
15N-edited and
13C-edited
NOESY were acquired with mixing times of 100 and 130 ms,
respectively. To identify the slowly exchanging amides, a
15N-
labeled sample was lyophilized and dissolved in 99.96% D2O.
Immediately, a series of
1H-
15N HSQC were recorded to monitor
the attenuation of NH signals. NMR data were processed using
NMRPipe and NMRDraw [24], and then analyzed using Sparky
3 [25]. All software was run on a Linux system.
3D
15N-edited and
13C-edited NOESY spectra were used to
determine the NMR distance restraints for structure calculations.
Backbone torsion angle restraints were predicted from chemical
shifts of five types of nuclei:
13Ca,
13Cb,
13CO,
1Ha, and
15NH by
using TALOS+ [26]. Hydrogen bond restraints were obtained by
identifying slow-exchange amide protons after 12 hours’ incuba-
tion following solvent exchange. For hydrogen bonds, two distance
restraints were used: 2.0 A ˚ for H-O and 3.0 A ˚ for N-O. Structures
were calculated using the program CYANA 3.0 [27]. A total of
200 conformers were independently calculated, and 20 lowest-
energy structures were selected and analyzed by MOLMOL [28]
and PROCHECK [29] online (http://nihserver.mbi.ucla.edu/
SAVES_3/).
Chemical shift perturbation
To identify the residues responsible for binding to tyrosine-
phosphorylated or nonphosphorylated DLC-1 peptide in tensin2
SH2 domain, 0.5 mM
15N-labeled protein were titrated with
unlabeled tyrosine-phosphorylated or nonphosphorylated peptide
to different molar ratios (1:0, 1:1, 1:2 and 1:3, SH2/peptide).
1H-
15N HSQC spectrum was acquired for analysis. Peptide stock
solutions in identical buffer were titrated stepwise with a sample
dilution of less then 10%. Combined chemical shift pertur-
fobation was calculated using the following equation: Ddppm~ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
(DdHN)
2z(0:17DdN)
2
q
. DdNH and DdN are the chemical shift
variation in the proton and nitrogen dimensions, respectively. The
threshold values used as a criterion for significance were 60% for
intensity reduction and 0.1 ppm for chemical shift perturbation.
Results
Comparison of the primary sequence of the SH2 domain
between tensins and other proteins
The SH2 domains have been found in hundreds of proteins
involved in a variety of cellular processes. The SH2 domains from
different proteins share low sequence identity (Figure 1A). For
Figure 1. Multiple sequence alignments between different SH2 domains of proteins from different species. Alignments were
performed using ClustalW2 and ESPript 2.2. Identical residues were shaded in red box. A. SH2 domains share low primary sequence similarity, but
similar secondary structure. B. SH2 domains of tensin family members share high primary sequence similarity.
doi:10.1371/journal.pone.0021965.g001
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induced signal-transduction events in T lymphocytes shares only
about 24% sequence identity with tensin2 SH2 domain. The
sequence diversity of the SH2 domains may reflect their ability of
binding various ligands in different cellular processes. Although
the SH2 domains vary dramatically in sequence and ligand
recognition, the SH2 domains from different tensin family
members display 70%–80% of sequence identity between each
other (Figure 1B), which may imply their common properties not
only in structure but also in ligand recognition.
Interactions between tensin2 SH2 domain and DLC-1
peptides
Recently, the SH2 domain of tensin family protein cten that is
able to bind DLC-1 peptides in a pTyr independent manner has
been reported [12,13]. To understand whether the SH2 domain of
another tensin family member, tensin2, binds to the same ligand
and whether this binding is also phosphorylation-independent, we
investigated the interactions between tensin2 SH2 domain and
non/phosphorylated DLC-1 peptides by SPR. The results
indicated that tensin2 SH2 domain bound specifically to both
phosphorylated and nonphosphorylated peptides. The equilibrium
dissociation constant (KD) derived from kinetic analyses was about
248.0068.82 nM for SH2-nonphosphorylated peptide interaction
(Figure 2A) and 31.0060.50 nM for SH2-phosphorylated peptide
interaction (Figure 2B). It was surprising that phosphorylation of
DLC-1 peptide increased its affinity to tensin2 SH2 domain by
only eight folds approximately under the condition for SPR
experiments, whereas for typical SH2 domain, the affinity of
tyrosine-phosphorylated peptide to the SH2 domain is about four
orders of magnitude greater than that of nonphosphorylated
counterpart [7,30]. This result indicated that the peptide
recognition of tensin2 SH2 domain was relatively phosphorylation
independent.
Secondary structures of tensin2 SH2 domain in free form
and in complex with DLC-1 peptides
To investigate the secondary structure of tensin2 SH2 domain
and its change upon binding to ligand, CD experiments were
performed. The CD spectra of tensin2 SH2 domain in complex
with non/phosphorylated DLC-1 peptides in different ratios
indicated that there was no significant change in the secondary
structure of tensin2 SH2 domain after binding to the ligands
(Figure 3A and Figure 3B).
Figure 2. Kinetic analyses of interactions between tensin2 SH2 domain and nonphosphorylated/phosphorylated peptides by SPR.
Kinetic analyses of interactions between peptides and tensin2 SH2 domain were performed at 6 steps of concentration of recombinant SH2 domain
at a flow rate of 30 mL/min for 2 mins. A. SPR spectra of the SH2 domain binding to nonphosphorylated peptide. B. SPR spectra of the SH2 domain
binding to phosphorylated peptide. Analyses were performed three times at each step of concentration. KD of the SH2 domain binding different
peptide was derived from kinetic analysis.
doi:10.1371/journal.pone.0021965.g002
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Tensin2 SH2 domain, including residues from 1135 to 1248 of
the protein, was recombinantly expressed and purified. The
recombinant product exhibited good solubility and stability. The
solution structure of tensin2 SH2 domain was calculated based on
a series of NMR spectra. The NMR data used for structure
calculations are summarized in Table 1. The chemical shift
assignments of tensin2 SH2 domain have been deposited in the
Biological Magnetic Resonance Data Bank (accession number
17314). The assembly of the 20 lowest-energy structures is shown
in Figure 4A. Structures of tensin2 SH2 domain have been
deposited in Protein Data Bank (PDB ID code 2l6k). The statistical
Figure 3. CD spectra of tensin2 SH2 domain free and in complex with peptides. A. CD spectra of tensin2 SH2 domain with
nonphosphorylated peptide in different molar ratios (blue, green, red and cyan represent SH2/peptide ratios of 1:0, 1:1, 1:2 and 1:3, respectively).B .
CD spectra of the SH2 domain with phosphorylated peptide in different molar ratios (blue, green, red and cyan represent SH2/peptide ratios of 1:0,
1:1, 1:2 and 1:3, respectively).
doi:10.1371/journal.pone.0021965.g003
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tensin2 SH2 domain. Calculated structure of tensin2 SH2 domain
shows a characteristic SH2 fold, which includes the two main a-
helices packing against either side of a central b sheet. The lowest-
energy structure was shown in Figure 4B. The central b sheet is
composed of three long antiparallel b strands (bB, bC, bD)
followed by one short antiparallel b strand (bE) and one shorter b-
sheet-like structure (bF). The two main a-helices (aB and aC) flank
either side of the central b sheet. The residues composing
secondary structures are listed as follows: residue 4 to 7 (aA),
residue 8 to 9 (bA), residue 13 to 22 (aB), residue 29 to 33 (bB),
residue 40 to 46 (bC), residue 66 to 72 (bD), residue 78 to 81 (bE),
residue 87 to 89 (bF) and residue 91 to 98 (aC), from N-terminus
to C-terminus.
Structural comparison with other SH2 domains
As the SH2 domains of tensin2 and SAP both interact with
ligands in a pTyr-independent way, the structure of free SAP was
used to perform structural compare. The alignment of SAP and
the lowest-energy structure of tensin2 SH2 domain was shown in
Figure 5. Although the two SH2 domains share low sequence
identity, both structures show typical SH2 fold, with a central five
b strands flanked by two a helices at either side, which
demonstrated that the SH2 domain is a structurally conserved.
A DALI [31] search using tensin2 SH2 domain as query sequence
indicates that SH2 domains share high similarity in 3D-structure.
The RMSD and Z-score between tensin2 SH2 domain and SAP
are 2.4 A ˚ and 10.8, respectively. The structural difference between
these two SH2 domains lies in the loop between bC and bD.
Tensin2 SH2 domain has a longer loop than SAP, implying that
the former structure might be more flexible than that of the latter
in this region.
Identification of the residues of tensin2 SH2 domain
involved in binding to DLC-1 peptides
To determine the residues in tensin2 SH2 domain involved in
recognition of non/phosphorylated DLC-1 peptides, chemical
shift perturbation experiments were performed.
1H-
15N HSQC
experiments were recorded for
15N-labeled tensin2 SH2 domain
before and after addition unlabeled nonphosphorylated or
phosphorylated peptides to different molar ratios of SH2/peptide.
The spectral changes that occurred after peptide addition were
characterized by resonance intensity reductions and chemical shift
changes. The residues of tensin2 SH2 domain interacting with
nonphosphorylated ligand were signified by the obviously reduced
peak intensity. Compared with it, the residues of tensin2 SH2
domain interacting with phosphorylated ligand were signified by
the substantial resonance shift (Figure 6A to 6C). The amino acids
affected in the presence of the nonphosphorylated ligand were
residues Leu12, Ala17, Ile18 (belong to aB), Leu30-Arg32 (belong
to bB), Ser34, Ser36-Gly39 (belong to BC loop), Ala40, Gly42-
Lys46 (belong to bC), Val47-Thr49, Ser53, Gln55, Asp60, Val62-
Gln64 (belong to CD loop), Val66, Arg67, Phe69-Glu72 (belong to
bD), Thr73, Gly74 (belong to DE loop), Val78, Ile80, Lys81
(belong to bE), Gly82 (belongs to EF loop), Phe89 (belongs to bF),
Leu95, Val96, Gln98 (belong to aC) and Cys108 (belongs to C-
terminal coil) (Figure 6B). The amino acids affected in the
presence of phosphorylated ligand were residues Lys9 (belongs to
bA), Leu12, Arg14, Ala17, Ile18 (belong to aB), Ile31-Asp33
(belong to bB), Ser34, Ser36-Gly39 (belong to BC loop), Ala40,
Gly42-Lys46 (belong to bC), Val47-Thr49, Ser53-Gln55, Asp60,
Glu63, Gln64 (belong to CD loop), Val66, Arg67, Phe69-Ile71
(belong to bD), Thr73, Gly74 (belong to DE loop), Ile80, Lys81
(belong to bE), Gly82, Cys83 (belongs to EF loop), Phe89 (belongs
to bF), Leu95, Gln98 (belong to aC) and Cys108 (belongs to C-
terminal coil) (Figure 6C). These residues might be involved in the
interactions between tensin2 SH2 domain and the ligands. The
distribution of the residues which showed intensity reductions in
the presence of nonphosphorylated ligand was almost identical to
that of residues which showed chemical shift perturbations in the
presence of phosphorylated ligand, which might reflect the similar
binding pattern of tensin2 SH2 domain to peptides with different
phosphorylation status.
Tyr41 of tensin2 SH2 domain was shown to be affected both in
the presence of phosphorylated and nonphosphorylated ligands in
chemical shift perturbation experiments. Meanwhile, it has been
reported previously that tensin3 SH2 domain’s Tyr1206, which
was the counterpart of Tyr41 in tensin2 SH2 domain, is important
for ligand binding [14]. Therefore, we mutated the Tyr41 residue
to Ser residue and tested how this mutation affected their
interactions. The equilibrium dissociation constant (KD) derived
from SPR experiment was about 16.0060.20 mM for the Y41S
mutant-nonphosphorylated peptide interactions (Figure S1A) and
5.0060.04 mM for the Y41S mutant-phosphorylated peptide
interactions (Figure S1B). The KD value of Y41S mutant-ligands
Table 1. NMR structural statistics.
NMR restraints in the structure calculation
Intraresidue 333
Sequential (|i - j| =1) 447
Medium-range (|i - j| ,5) 252
Long-range (|i - j| ./=5) 369
Hydrogen bonds 66
Total distance restraints 1580
Dihedral angle restraints 113
Residual violations
CYANA target functions, A ˚ 1.4360.24
NOE upper distance constrain violation
Maximum, A ˚ 0.2060.04
Number .0.2 A ˚ 061
Dihedral angle constrain violations
Maximum, u 3.2360.72
Number .5u 060
Vander Waals violations
Maximum, A ˚ 0.3060.00
Number .0.2 A ˚ 361
Average structural rmsd to the mean coordinates, A ˚
Secondary structure backbone
a 0.31
Secondary structure heavy atoms
a 0.80
All backbone atoms
b 1.30
All heavy atoms
b 1.79
Ramachandran statistics, %of all residues
Most favored regions 81.5
Additional allowed regions 18.5
Generously allowed regions 0
Disallowed regions 0
aIncludes residues in secondary structure.
bObtained for residues T3-R111 since no long-range NOEs were identified for
amino acid 1–2 and 112–115.
doi:10.1371/journal.pone.0021965.t001
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domain-ligands, which suggested an important role of Tyr41 of
tensin2 SH2 domain both in the recognition of the nonpho-
sphorylated and phosphorylated ligands.
Based on chemical shift perturbation, the structure of tensin2
SH2 domain was shown with residues marked to display the ones
involved in peptide interaction (Figure 7). It is remarkable that the
majority of significantly affected residues, such as Leu30, Ile31,
Figure 4. The NMR structure of tensin2 SH2 domain. A. Superposition of 20 lowest-energy NMR structures. B. The lowest-energy conformation
used for ribbon representation on highlighting the six b-strands and two main a-helices that are identified in tensin2 SH2 domain.
doi:10.1371/journal.pone.0021965.g004
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whose intensity reductions were higher than 70% even to 100%
and Ser34, Gly39, Ala44, Lys46, Glu63 whose chemical shift
perturbations were bigger than 0.3 ppm, were located in the
central anti-parallel b-sheet and the loops between b strands.
These sites are the conserved binding sites for typical SH2
domains recognizing their ligands. In addition, residues Lys9
(belongs to bA), Leu12, Arg14, Ala17 and Ile18 (belong to aB),
which are located outside the central region, displayed discernable
changes during titration as well. These residues may also
participate in the interactions between tensin2 SH2 domain and
its ligands.
Discussion
Tensin is a family containing four members that are localized to
the cytoplasmic side of focal adhesions and play essential roles in
extracellular matrix based signaling pathway. Previous studies
have suggested cten, a tensin family member, may function as a
tumor suppressor, through the interaction with DLC-1 [13] that
has been found to be absent or suppressed in many cancers such as
hepatocellular carcinoma (HCC). However, more recent studies
revealed other roles of cten as an oncogene in colorectal cancer
through enhancing the colony formation, anchorage-independent
growth, cell migration and invasion [32,33]. Mutations in DLC-1
which disrupt its interaction with cten SH2 domain will abolish its
role as a tumor suppressor [34]. Thus, cten is important for the
functions of DLC-1 in tumor suppression. In addition, tensin3 has
also been reported to be involved in tumorigenesis [14]. In this
study, we indicate that another member of tensin family, tensin2, is
able to interact through its SH2 domain with DLC-1 as well; and
the interaction is pTyr-independent, similar to cten SH2 domain.
The interaction of tensin2 SH2 domain with tumor suppressor
DLC-1 might reflect the general roles of tensin family members in
preventing tumor development.
So far, no structure has been reported for the SH2 domains of
tensin family proteins. Though the sequence similarity between
tensin members is low, their SH2 domains share high sequence
identity, which implies they might possess conserved structure. In
this study, we reported the NMR solution structure of tensin2 SH2
domain. The structure is mainly composed of five b-strands
flanked by two a-helices at either side, which is a characteristic of
typical SH2 domain, suggesting that SH2 domain family is highly
conserved in structure.
Although tensin2 SH2 domain adopts a similar structure to other
SH2 domains, it recognizes its ligand in a pTyr-independent instead
of pTyr-dependent manner. SAP, which has only one SH2 domain,
was the first protein reported to interact with ligand in a pTyr-
independent manner. The interaction mechanism has been dis-
closed by analyzing its free structure and complex structures with
phosphorylated/nonphosphorylated ligands. A theory called ‘‘three-
pronged plug and socket’’ was proposed to illustrate the pTyr-
independent interaction. This theory suggests three distinct regions
on SAP mediate specific interaction with N-terminus, residue Tyr,
and C-terminus of ligand, respectively [35]. Ligands of SAP share a
motif of ‘‘T/S-I-Y-X-X-V/I’’ (X represents any residue) [35].
Although the SH2 domain of tensin2 shares only about 24% of the
primary sequence identity with that of SAP, the ligand of tensin2 SH2
domain, DLC-1, contains the motif of ‘‘T/S-I-Y-X-X-V/I’’ as well,
w i t h i nt h es e q u e n c eo f‘ ‘ C S R L SIYDNVPG’’. The same motif
Figure 5. Structural comparison of tensin2 and SAP SH2 domains. The structure of SAP SH2 domain was shown in limon. The lowest-energy
conformation of tensin2 SH2 domain was shown in cyan. The alignment was performed by using Pymol.
doi:10.1371/journal.pone.0021965.g005
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PLoS ONE | www.plosone.org 8 July 2011 | Volume 6 | Issue 7 | e21965Figure 6. Identification of residues of tensin2 SH2 domain for binding to nonphosphorylated/phosphorylated ligands. A. The
1H-
15N
HSQC spectra of the
15N-labeled tensin2 SH2 domain free (red) and titrated with its ligand (left: nonphosphorylated peptide; right: phosphorylated
peptide) (green) were overlaid. B. The ratio of peak intensity after compared with before the addition of nonphosphorylated peptide. C. The chemical
shift changes after the addition of phosphorylated peptide. All the comparison was performed at the SH2/peptide molar ratio of 1:3. The broken lines
represent the significance level of intensity reductions .60% (intensity ratios ,40%) and chemical shift changes .0.1 ppm, respectively. The residues
that had significant changes and were untraceable in
1H-
15N HSQC spectra after the addition of phosphorylated peptide were labeled with w; the
residues that could not be assigned were labeled with q.
doi:10.1371/journal.pone.0021965.g006
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interact with ligands in a similar way.
ClassicalSH2domainsbind to phosphorylated peptidesthrougha
conventional phosphotyrosine-binding pocket. In our study, chem-
ical shift perturbation and structural comparison indicate that
tensin2 SH2 domainmaintains thisgeneral binding feature.The two
conserved binding regions existing in tensin2 SH2 domain are as
follows: (1) Residues binding to DLC-1 ligands regardless of the
phosphorylation status are located in the central anti-parallel b-
sheets and the loops between bBa n dbC, including Leu30, Ile31,
Arg32, Asp33, Ser34, Ser36, Phe37, Gln38, Gly39, Ala40, Tyr41,
Gly42, Leu43, Ala44, Leu45 and Lys46. These residues might form
the pTyr or Tyr binding site.Notably,Arg32,inbB strandoftensin2
SH2domain,which isalsopresentinotherSH2 domains,isessential
for recognition of the Tyr residue of ligand. (2) Residues (including
Ile80, Lys81, Gly82, Phe89 and Cys108) located in bE, bF, the loop
between bEa n dbF, and C-terminal coiled coil that correspond to
so-called ‘‘specificity determine region’’ might be responsible for the
interactions between tensin2 SH2 domain and C-terminus of ligand.
Additionally, the third group of residues, located in bAa n daB,
including Lys9, Leu12, Arg14, Ala17 and Ile18, were identified.
Similar as those of SAP SH2 domain, these residues may participate
in recognizing the N-terminus of ligand and be required for its
specific phosphorylation-independent binding.
In summary, we determined the solution structure of tensin2 SH2
domain and identified the pTyr-independent interactions between
tensin2 SH2 domain and DLC-1fragment. Our data imply the SH2
domains of tensin family might have conserved structure, common
mechanism of ligand recognition in a pTyr-independent way.
Supporting Information
Figure S1 Kinetic analyses of interactions between
mutated tensin2 SH2 domain and nonphosphorylated/
Figure 7. Molecular surface and ribbon representation of tensin2 SH2 domain displaying residues involved in its interaction with
nonphosphorylated/phosphorylated ligand. A. Molecular surface of tensin2 SH2 domain. B. Ribbon representation of tensin2 SH2 domain.
Molecular surface and ribbon representation of tensin2 SH2 domain were rotated by 180u horizontally. Residues marked in blue corresponded to the
ones involved in the interactions with both nonphosphorylated and phosphorylated ligands.
doi:10.1371/journal.pone.0021965.g007
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PLoS ONE | www.plosone.org 10 July 2011 | Volume 6 | Issue 7 | e21965phosphorylated peptides by SPR. Kinetic analyses of
interactions between peptides and mutated tensin2 SH2 domain
were performed at 6 steps of concentration of recombinant SH2
domain at a flow rate of 30 mL/min for 2 mins. A. SPR spectra of
the mutated SH2 domain (Y41S) binding to nonphosphorylated
peptide. B. SPR spectra of the mutated SH2 domain (Y41S)
binding to phosphorylated peptide. Analyses were performed three
times at each step of concentration. KD of the SH2 domain
binding different peptide was derived from kinetic analysis.
(TIF)
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